Literature DB >> 3899456

Effect of acute and chronic exercise on hepatic drug metabolism.

M Døssing.   

Abstract

Recent research indicates that physical exercise and fitness are new host factors with impact on hepatic drug metabolism, contributing to the intra- and interindividual variation in drug response. Moderate to heavy physical exercise for a few hours reduces liver blood flow as assessed by indocyanine green clearance, leading to a decreased elimination of drugs exhibiting flow-limited metabolism (high clearance drugs) such as lignocaine (lidocaine). However, hepatic elimination of drugs exhibiting capacity-limited metabolism (low clearance drugs) such as antipyrine (phenazone), diazepam and amylobarbitone (amobarbital) is not affected by acute physical exercise. Improved physical fitness as expressed by the maximum oxygen uptake seems to increase the elimination rate of the low clearance drug antipyrine and possibly also aminopyrine, while investigations of the biotransformation of high clearance drugs are contradictory. The sum of research in this recent field is rather limited and the mechanism whereby changes in physical fitness influence hepatic drug metabolism needs to be established. It is not known if other liver functions are changed. If the findings also apply for drugs with a low therapeutic index, there may be a risk of exercise-induced changes in drug efficacy and toxicity. It is suggested that future studies on host factors influencing drug metabolism should include information on physical activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899456     DOI: 10.2165/00003088-198510050-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  31 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

Review 2.  Human cardiovascular adjustments to exercise and thermal stress.

Authors:  L B Rowell
Journal:  Physiol Rev       Date:  1974-01       Impact factor: 37.312

3.  The influence of dose on the distribution and elimination of amylobarbitone in healthy subjects.

Authors:  K Balasubramaniam; G E Mawer; P J Simons
Journal:  Br J Pharmacol       Date:  1970-11       Impact factor: 8.739

Review 4.  Adaptations of skeletal muscle to endurance exercise and their metabolic consequences.

Authors:  J O Holloszy; E F Coyle
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1984-04

5.  Hepatic drug metabolism and physical fitness.

Authors:  J Boel; L B Andersen; B Rasmussen; S H Hansen; M Døssing
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

6.  Exercise-induced amenorrhea and bone density.

Authors:  J S Lindberg; W B Fears; M M Hunt; M R Powell; D Boll; C E Wade
Journal:  Ann Intern Med       Date:  1984-11       Impact factor: 25.391

7.  Drugs--some basic concepts.

Authors:  G D Sweeney
Journal:  Med Sci Sports Exerc       Date:  1981       Impact factor: 5.411

8.  Changes in circulating thyroid hormones during short-term hepatic enzyme induction with carbamazepine.

Authors:  J M Connell; W G Rapeport; S Gordon; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Effect of exercise on thyroid parameters and on metabolic clearance rate of antipyrine in man.

Authors:  P Theilade; J M Hansen; L Skovsted; J P Kampmann
Journal:  Acta Endocrinol (Copenh)       Date:  1979-10

10.  Sources of interindividual variations in acetaminophen and antipyrine metabolism.

Authors:  R M Nash; L Stein; M B Penno; G T Passananti; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1984-10       Impact factor: 6.875

View more
  15 in total

Review 1.  Effects of obesity on pharmacokinetics implications for drug therapy.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  The effect of exercise on atropine pharmacokinetics.

Authors:  G H Kamimori; R C Smallridge; D P Redmond; G L Belenky; H G Fein
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Influence of exercise on the pharmacokinetics of drugs.

Authors:  M A van Baak
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 4.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

5.  The effects of moderate sustained exercise on the pharmacokinetics of nitroglycerine.

Authors:  S Weber; D de Lauture; E Rey; T Darragon; J P Severins; A Ditisheim; G Olive; M Degeorges
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

Review 6.  Principles of pharmacotherapy: II. Pharmacokinetics.

Authors:  T J Pallasch
Journal:  Anesth Prog       Date:  1988 Jul-Aug

7.  Influence of exercise on nitroglycerin plasma concentrations after transdermal application.

Authors:  R A Lefebvre; M G Bogaert; O Teirlynck; A Sioufi; J P Dubois
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

8.  Indocyanine green (ICG) test before and after exercise in patients with chronic liver diseases.

Authors:  M Nambu; T Iijima
Journal:  Gastroenterol Jpn       Date:  1990-04

Review 9.  Potential interactions between exercise and drug therapy.

Authors:  Thomas L Lenz; Nancy J Lenz; Michele A Faulkner
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

10.  Effect of wheel-running during abstinence on subsequent nicotine-seeking in rats.

Authors:  Victoria Sanchez; Catherine F Moore; Darlene H Brunzell; Wendy J Lynch
Journal:  Psychopharmacology (Berl)       Date:  2013-01-31       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.